It remains controversial whether this increased risk was an expression of the natural ALK-rearranged disease course independent of the therapy received, or if, as in EGFR-mutant NSCLC patients, it is related to low CSF penetrance of ALK TKIs. The gene discussed is ALK; the disease is non-small cell lung carcinoma.